

Minireview

Prevalence of Chronic Atrophic Gastritis in Different Parts of the World

Melanie Nicole Weck and Hermann Brenner

Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany

Abstract

Chronic atrophic gastritis (CAG) is a well-established precursor of intestinal gastric cancer, but epidemiologic data about its occurrence are sparse. We provide an overview on studies that examined the prevalence of CAG in different parts of the world. Articles containing data about the prevalence of chronic atrophic gastritis in unselected population samples and published until November 2005 were identified by searching the MEDLINE database. Furthermore, the references in the identified publications were screened for additional suitable studies. Studies comprising at least 50 subjects were included. Forty-one studies providing data on the prevalence of CAG in unselected population samples could be identified. CAG was determined by gastroscopy in 15 studies and by pepsinogen serum levels in 26 studies.

Although results are difficult to compare due to the various definitions of CAG used, a strong increase with age, the lack of major gender differences, and strong variations between populations and population groups (in particular, relatively high rates in certain Asian populations) could be observed quite consistently. We conclude that CAG is relatively common among older adults in different parts of the world, but large variations exist. Large-scale international comparative studies with standardized methodology to determine CAG are needed to provide a coherent picture of the epidemiology of CAG in various populations. Noninvasive measurements of CAG by pepsinogen levels may be particularly suited for that purpose. (Cancer Epidemiol Biomarkers Prev 2006;15(6):1083–94)

Introduction

Chronic atrophic gastritis (CAG) plays a crucial role in the development of intestinal gastric cancer, the most common type of gastric cancer, which continues to be one of the leading cancer causes of death in the world. Mortality rates of gastric cancer are particularly high in Asia, South America, and parts of Europe (1). It is well established that gastric carcinogenesis is a continuous process leading from nonatrophic gastritis to glandular atrophy (loss of specialized glands), to metaplasia and dysplasia, and finally to adenocarcinoma (2, 3). This process usually takes decades and seems to be initiated by infection with the gastric bacterium *Helicobacter pylori* in many if not most cases (4–7). The long-term development may thus potentially provide opportunities for early detection of precancerous lesions and intervention. However, because the majority of individuals carrying CAG do not suffer from any symptoms, CAG and early-stage gastric cancer remain unrecognized in most cases.

Presence of CAG may be determined either by gastroscopy with subsequent histologic analysis of obtained biopsies (8) or by investigating the pepsinogen (PG I and PG II) concentrations in serum (9, 10); both PG I and the PG I/PG II ratio are decreased in CAG. A number of epidemiologic studies have meanwhile assessed the prevalence of CAG in different populations, but the selection of study samples and the definitions of CAG have been quite diverse. In this article,

we provide a comprehensive review of published data on the prevalence of chronic atrophic gastritis, with particular attention to differences and similarities in the methods used. We thereby aim to delineate the current state of knowledge regarding the epidemiology of CAG and the need for further investigation.

Materials and Methods

Studies investigating the prevalence of chronic atrophic gastritis were identified by searching for articles in the MEDLINE database, using various combinations of the terms "chronic atrophic gastritis," "CAG," "prevalence," "atrophic gastritis," "atrophic," "gastritis," "(gastric) atrophy," "pepsinogen(s)," "precancerous lesion(s)," "stomach," and "(mass) screening." The references in the thus acquired articles were also screened for suitable studies (cross-referencing). The analysis was restricted to studies published in English until November 30, 2005.

To ensure reasonable levels of precision of prevalence estimates, we excluded studies with <50 participants. We also excluded studies where patients were preselected according to gastrointestinal symptoms (e.g., gastroscopy-based studies where gastroscopy was employed due to symptoms rather than as a primary screening tool). These criteria were employed to avoid biased estimates of prevalences.

Information retrieved from the publications are place and time of the study, constitution of the study population, number of participants, male/female ratio, age (range and mean), type of measurement of CAG, and criteria for diagnosis. Whenever possible, the prevalence of CAG was extracted in terms of an overall value and stratified by gender, by age, and by location of the lesion (latter for gastroscopy screenings only). In some of the publications, the actual numbers were not stated but could be derived from published graphs.

Received 12/12/05; revised 3/13/06; accepted 3/29/06.

Grant support: German Research Foundation (DFG) within the framework of the Graduiertenkolleg 793.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Requests for reprints: Hermann Brenner, Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Bergheimer Straße 20, D-69115 Heidelberg, Germany. Phone: 49-6221-548140; Fax: 49-6221-548142. E-mail: h.brenner@dkfz-heidelberg.de

Copyright © 2006 American Association for Cancer Research.

doi:10.1158/1055-9965.EPI-05-0931

According to type of measurement of CAG, the studies were grouped into gastroscopy-based screenings with subsequent histologic examination on one hand and in studies that determined serum pepsinogen levels on the other hand. Prevalences extracted from the gastroscopy-based studies include both CAG with and without more advanced lesions.

Results

The literature search identified 89 studies providing data about CAG prevalences. Of these, 48 studies were excluded from this review for the following reasons: preselection of study population due to symptoms (44 studies) and size of the study population (four studies). References of excluded studies are given in Appendix 1.

As the numbers indicate, the selection of the study participants turns out to be the most critical criterion. It was paid close attention to exclude all studies showing any evidence of a preselection of participants related to gastritis. Nevertheless, not all included studies do include perfectly representative population samples. Study samples also accepted were blood donors, elderly people, hospital workers, industry workers, smokers, and people taking part in an annual health examination or a CVD screening and self-defense forces. These primarily non-population-based study populations were tolerated because even a selection via population registers cannot assure perfect random samples when taking response rates into account.

Among the 41 studies that met the inclusion criteria, there are 15 gastroscopy-based studies (11-28) and 26 studies measuring pepsinogen concentrations (29-60). In all but two of the latter, pepsinogen levels were measured by RIA; in the studies by Sipponen et al. (54) and Green et al. (59), measurements were done by enzyme immunoassay. Not all of the studies had the primary intention to determine the CAG prevalence. Some of the studies collected the data primarily for other purposes, such as to study the role of CAG and other risk factors in the development of gastric cancer (15, 18, 19, 32, 33, 35, 37, 43, 55, 56), or to assess the association of CAG with *H. pylori* infection (25, 44). An overview on the studies is given in Table 1 (gastroscopy-based studies) and Table 2 (studies based on serum pepsinogen levels), respectively.

Due to use of different methods of measurements and varying definitions and cut points, a direct comparison of prevalences among the studies is difficult. Despite this difficulty, a number of patterns become apparent when looking at the data.

Gastroscopy-based studies have been conducted in all continents except for Africa, with a main focus on high-risk areas of gastric cancer. In detail, they were done in Asia [Japan (25) and China (22, 26)], in Europe [Finland (11, 14), Estonia (12, 16), the Netherlands (13), Norway (20), Sweden (27), Italy (15, 18), and Hungary (15)], in Columbia (19), in Iran (28), and in Australia (24), with the first study being published in 1968 by Siurala et al. (11) from Finland. The number of participants varied widely among the different studies. By inclusion criteria, the smallest study population enclosed 50 participants. Most of the gastroscopy-based studies comprised between 100 and 250 participants, but there were also three studies examining >1,000 persons, the maximum number being 3,400. One study was restricted to males, all others comprised both males and females. The age of participants varied considerably among the studies because some population registry-based studies investigated people with an age range from 16 to 69 years, but narrower age ranges were included in several other studies.

Prevalence rates vary widely between the populations screened by gastroscopy and even within population groups.

Although most studies show prevalences below 50%, some studies conducted in Japan and China reveal much higher prevalences (22, 25, 26). An increase of CAG prevalence with age was consistently found in most studies looking at age-specific prevalences. However, two studies (22, 26) from a Chinese population with one of the world's highest rates of stomach cancer showed prevalences of CAG or even more advanced lesions close to 100% even among the youngest of the included age groups. Most studies do not reveal any differences between males and females. Except for one study (16), CAG was always more frequent in the antrum than in the fundus/corpus.

Measurement of pepsinogen serum levels was carried out by 11 studies in Japan (33, 35, 44, 49, 51-53, 55-58), two studies among Japanese living abroad (48, 50), several others in Europe [United Kingdom (31, 40), Italy (32), Finland (43, 46, 54) and the Netherlands (47)], two in the United States (29, 45), and one in New Zealand (59). International comparative studies included population samples from 13 (37), 4 (60), and 2 (42) nations, respectively. The period of pepsinogen-based studies started about 20 years later than the gastroscopy based studies, with the first pepsinogen-based prevalence study being published by Krasinski et al. (29) in 1986. Studies measuring serum pepsinogen levels, which are both less invasive and less costly than gastroscopy-based screening, mostly included much larger study populations. The smallest sample comprised 105 persons, and eight studies, six studies, and two studies included between 500 and 1,000, between 1,000 and 10,000, or even >10,000 persons, respectively. Most of the studies included both genders, eight studies were restricted to males. The age of participants that were included varied considerably among the different studies. Some studies investigated people with broad age ranges, such as from 20 to 86 years, but much narrower age ranges were included in other studies, such as age groups 25 to 34 and 55 to 64 years, which were included in the largest international comparative study (37).

Prevalences determined in the pepsinogen-based studies may be influenced by factors that modify pepsinogen levels, and prevalences are comparable only as far as identical cut points are used. The very low prevalences found in the EUROGAST study (37), an international comparative study, including 17 populations from 13 countries, primarily reflect the very restrictive cut point used in this study (PGI < 25 ng/mL), which delineates quite severe forms of CAG. Apart from Algeria, prevalences of severe CAG were below 5% in age groups 25 to 34 in all countries included in this study, but ranged up to 11% in age group 55 to 64. Prevalences were higher in Algeria (10.4% and 16.0% in age groups 25 to 34 and 55 to 64, respectively) and Japan than in European and U.S. populations, and there was major variation even within different populations from Japan. Much higher prevalences delineating less severe forms of CAG were found in studies with less restrictive pepsinogen cut points of CAG. An increase of prevalence with age was observed by most of the studies. Most studies did not detect relevant differences in gender, even after stratification by age. Interestingly, the multicenter EUROGAST study (37) detected a higher (or equal) prevalence for women in all 17 populations except for Italy and one population in Japan, but these mostly small differences have to be interpreted with caution given the relatively low number of subjects within the populations. This study is also the only pepsinogen-based study that analyzed age-specific differences by sex, and it found a significantly increased prevalence for women versus men ($P = 0.002$) in the age group of 25 to 34 but not in the age group of 55 to 64 years (all nations combined).

Time trends in prevalence of CAG can only be judged from studies applying the same methodology in comparable

Table 1. Gastroscopy-based studies

Author(s), year (ref.*)	Study population				Prevalence of CAG in %				Performance of gastroscopy and histology [§]
	Country (time of survey)	Setting	No. participants (gender), response rate	Age (mean)	Overall (severe)	By sex (severe)	By age ^{†,‡} (severe)	By location (severe)	
Siurala et al., 1968 (11, 16)	Finland (1966)	Population registry based	142 (M, 45.1%; F, 54.9%), 74%	16-65 (42)		M, 20.3; F, 34.6	Age: body 16-20: 6 21-30: 10 31-40: 21 41-50: 20 51-60: 51 61-65: 60	Body: 28 (2.8)	<ul style="list-style-type: none"> • Suction tube method (blind) • Mostly three biopsies per subj. • crit.: Siurala et al. (11)
Villako et al., 1976 (12, 16)	Estonia	Population registry based	155 (M, 38.0%; F, 62.0%), 62%	16-69 (46)			Age: fundus/ antrum 16-19: 0/29 20-29: 0/8 30-39: 11/11 40-49: 21/33 50-59: 27/42 60-69: 31/35	Fundus: 20 (6), antrum: 29 (1)	<ul style="list-style-type: none"> • Mostly four biopsies per subj. (fundus and antrum, each posterior and anterior wall) • crit.: Siurala et al. (11)
Kreuning et al., 1978 (13)	Netherlands	Hospital workers + "healthy" volunteers	50 (M, 54%; F, 46%)	20-58 (33)	34 (4)	M, 22; F, 43	20-29: 10 30-39: 31 40-49: 80 50-59: 50	Fundus: 30, antrum: 34	<ul style="list-style-type: none"> • Biopsies from seven standard sites • crit.: Whitehead (73)
Ihamaki et al., 1979 (14)	Finland	Population registry based (controls for GC relatives)	358 (M, 50.2; F, 49.8), 87%	15 to ≥66 (46.0)		Body/antrum: M, 13/26; F, 18/29	Age: body/ antrum 15-30: 6/10 31-50: 7/24 51-65: 27/44 ≥65: 42/49	Body: 16, antrum: 28	<ul style="list-style-type: none"> • Biopsies: at least three from antrum plus at least six from body • crit.: Siurala et al. (11)
Cheli et al., 1980 (15)	Italy	"Randomly chosen" (hospital based)	100		22		20-29: 6.7 30-39: 17.6 40-49: 22.2 50-59: 33.3 60-69: 18.8 70-79: 40.0		<ul style="list-style-type: none"> • Biopsies: one from fundus plus one from antrum • crit.: Valencia-Parparcen et al. (74)
	Hungary		100		37		20-29: 14.3 30-39: 22.2 40-49: 33.3 50-59: 29.4 60-69: 44.4 70-79: 80.0		
Villako et al., 1982 (16, 17)	Estonia (1979)	Population registry based	227 (M, 45.4%; F, 54.6%), 85%	15-69 (39.9)		Body/antrum: M, 41/38 [¶] ; F, 33/31 [¶]	Age: fundus/ antrum 15-19: 21/16 20-29: 20/29 30-39: 24/25 40-49: 35/35 50-59: 64/54 60-69: 67/45	Body: 37 (6), antrum: 34 (1)	<ul style="list-style-type: none"> • Biopsies: at least three from antrum plus at least six from body • crit.: Siurala et al. (11)
Cheli et al., 1986 (18)	Italy	Controls for duodenal ulcer patients (hospital based)	60 (M, 68%; F, 32%)	20-69 (42)			Age: fundus/ antrum <40: 7.2/3.6 >40: 25.0/25.0	Fundus: 16.6, antrum: 15.0	<ul style="list-style-type: none"> • Biopsies: three from body and two from antrum • crit.: Cheli et al. (77)

(Continued on the following page)

Table 1. Gastroscopy-based studies (Cont'd)

Author(s), year (ref.*)	Study population				Prevalence of CAG in %				Performance of gastroscopy and histology [§]
	Country (time of survey)	Setting	No. participants (gender), response rate	Age (mean)	Overall (severe)	By sex (severe)	By age ^{†, ‡} (severe)	By location (severe)	
Correa et al., 1990 (19)	Columbia (1973-1983)	Household based	1,670 (M, 49.9%; F, 50.1%)	15 to ≥55	45	M, 48; F, 41	15-24: 23 25-34: 37 35-44: 49 45-54: 64 ≥55: 59		<ul style="list-style-type: none"> • Multiple biopsies (at least four sites plus at gastroscopic suspect regions) • crit: Correa (75) and Correa et al. (76)
Johnsen et al., 1991 (20, 21)	Norway (1987)	Population registry based (controls for dyspeptic persons)	273 (M/F, ~ 50%/ 50%), 65%	20-69	50.5				<ul style="list-style-type: none"> • Biopsies from corpus and antrum, including both greater and lesser curvature • crit: Whitehead (72) and Owen (78)
You et al., 1993 (22, 23)	China (1989-1990)	Population registry based	3,400 (M, 52.7%; F, 47.3%), 93%	35-64	98.1		Age: male/female 35-39: 97.3/97.3 40-44: 98.4/98.2 45-49: 98.4/99.5 50-54: 97.7/100.0 55-59: 98.4/99 60-64: 100/99.2	Cardia: 48-58**, body: 29-66**, angulus: 82-83**, antrum: 76-90**	<ul style="list-style-type: none"> • Multiple biopsies (at least seven sites plus at gastroscopic suspect regions) • crit: You et al. (22)
Katellaris et al., 1993 (24)	Australia	Healthy volunteers (recruited via advertising)	50 (only men)	18-30 (mean 23) and ≥50 (mean 73)	22		18-30: 0 ≥50: 39	Fundus: 16, body: 16, antrum: 22	<ul style="list-style-type: none"> • Biopsies: four from antrum, three from corpus, four from fundus • crit: Sydney system (69)
Asaka et al., 1996 (25)	Japan	Health screening	85	30 to ≥60	52.9		Age: Hp ⁺ /Hp ⁻ ^{††} 30-39: 49/0 40-49: 60/12 50-59: 69/15 ≥60: 87/30		<ul style="list-style-type: none"> • Biopsies: paired biopsy specimen from antrum and corpus • crit: Sydney system (69, 71)
You et al., 1998 (26)	China (1994)	Population registry based	214 ^{††} (M, 50%; F, 50%)	35-64	82.2	M, 80.4; F, 84.1	35-39: 81.6 40-44: 80.9 45-49: 76.9 50-54: 86.6 55-59: 78.6 60-64: 87.0	Body: 13.2, angulus: 59.1, antrum: 70-79 ^{§§}	<ul style="list-style-type: none"> • Biopsies: 4 • crit: You et al. (22)
Borch et al., 2000 (27)	Sweden	Population registry based	501 (M, 55%; F, 45%), 25%	35-85	28 (8.2)		35-44: 8 45-54: 19 55-64: 21 65-74: 36 ≥75: 56		<ul style="list-style-type: none"> • Biopsies: three from body (major, anterior, posterior) and three from antrum (within 3 cm of pylorus) • crit: Sydney system (69, 70)

(Continued on the following page)

Table 1. Gastroscopy-based studies (Cont'd)

Author(s), year (ref.)*	Study population				Prevalence of CAG in %				Performance of gastroscopy and histology [§]
	Country (time of survey)	Setting	No. participants (gender), response rate	Age (mean)	Overall (severe)	By sex (severe)	By age ^{†,‡} (severe)	By location (severe)	
Malekzadeh et al., 2004 (28)	Iran (2000-2001)	Population registry based	1,001 (M, 48.9%; F, 51.1%), 91.5%	40-92 (53)				Cardia: 21.9, corpus: 46.9, antrum: 45.2	• Multiple biopsies (at least four sites plus at gastroscopic suspect regions) • crit.: Malekzadeh et al. (28)

Abbreviations: crit., criteria for diagnosis of CAG; F, female; GC, gastric cancer; M, male; subj., subject.

*When multiple references are listed: the first publication contains data on prevalence rates; the others contain information on additional extracted study details.

†Age-stratified data were derived from graphs in Kreuning et al. (13), Ihamaki et al. (14), and Asaka et al. (25).

‡Age-stratified data are subdivided in severe and nonsevere forms (data not shown in the table because numbers are too small) in Siurala et al. (11), Villako et al. (12), Ihamaki et al. (14), and Villako et al. (16).

§The numbers of biopsies refer to the aspired quantity; sometimes, not all of them could be obtained in a subject.

||Exact sites for biopsies: Kreuning et al. (13): (1) prepyloric; (2) minor curvature just above the angulus; (3) major curvature opposite to 2; (4) high up the minor curvature, just below the cardia; (5) antrum; (6) middle of corpus, posterior wall; (7) fundus. Cheli et al. (18): (1) middle portion of the lesser curvature, just proximal to the incisura; (2) high on the lesser curvature, 3 cm below the cardia; (3) middle portion of the greater curvature; (4) antral anterior wall, within 2 cm of the pylorus; (5) antral posterior wall within 2 cm of the pylorus. Correa et al. (19): (1) midportion of antral lesser curvature; (2) midportion of antral greater curvature; (3) transition zone; (4) midanterior wall of body; (5+) additional biopsies; (6+) gastroscopic suspect lesions. You et al. (22): (1) midway between cardia and angulus on the lesser curvature; (2) middle of the greater curvature of the corpus; (3) center of the angulus along the middle portion of the lesser curvature; (4) 1 cm from the pylorus along the lesser curvature; (5) posterior wall of the antrum; (6) anterior wall of the antrum; (7) greater curvature of the antrum; (8+) if severe lesions were visually at gastroscopy. You et al. (26): (1) greater curvature of the body, (2) angulus, (3) lesser curvature of the antrum, (4) greater curvature of the antrum. Malekzadeh et al. (28): (1) antrum between the incisura angularis and pyloric canal; (2) antrum, on the opposite of 1 over the greater curvature; (3) cardia, 0.5 to 1.0 cm below the gastroesophageal junction on the anterior wall; (4) same as 3 but on posterior wall; (5-6) in some subjects: corpus greater and lesser curvature; (7+) at all visible lesions.

¶Difference not significant.

**Variations in location-stratified values depend on sex and exact biopsy site.

††The age-stratified data are subdivided between *H. pylori*-infected subjects (Hp⁺) and those who are not infected (Hp⁻).

‡‡Only participants from Cangshan are included because results from Linqu are already analyzed in You et al. (22).

§§Variations in location-stratified values depend on the exact biopsy site.

samples of participants from the same country/region at various points of time. Such pepsinogen-based studies were reported by Kobayashi et al. (55) conducted in Japan in 1989/1990 and 1996, respectively, and revealed a decrease in age-specific CAG prevalences over time.

H. pylori infection in the study population was determined in four gastroscopy-based studies (24, 25, 27, 28) and in 17 pepsinogen-based studies (34, 35, 37, 40, 42-44, 47-53, 56, 58, 60). However, only the minority of them reported the prevalence of CAG by *H. pylori* infection.

Discussion

Although CAG is an important step in the development of intestinal gastric cancer, data on prevalence are rare and even lacking entirely for most countries of the world. Due to selection of study samples, to varying definitions of CAG used and to differing cutoff values available, results are difficult to compare even among the few studies reported to date. Nevertheless, it becomes clear that CAG is relatively common among the elderly population. In addition, strong variations between populations and population groups, with much higher rates in some Chinese and Japanese populations than in other parts of the world, as well as an increase with age and the absence of differences between males and females were detectable throughout.

The absence of differences by sex is surprising because men have an increased rate of gastric cancer compared with women (1, 19). Interestingly, reported prevalences even tended to be higher in women in the international EUROGAST study (37). However, this difference in gender seemed to be

partly due to body weight and disappeared after adjusting for it (37). Furthermore, in a study by Sipponen et al., the risk of developing gastric cancer was shown to be much smaller for women with CAG than for men with CAG (61). The increase in CAG with age may reflect progression of gastritis with age. However, it may also reflect a birth cohort effect, as pointed out by Sipponen (62): *H. pylori* gastritis is a birth cohort-related phenomenon, with different cohorts showing different prevalences. Higher CAG prevalences in cohorts born in the beginning of the century than in those born later may thus be caused by a decline in infection with *H. pylori* in younger birth cohorts. The much higher rates of CAG reported from Asian populations may also be related to the very high prevalence of *H. pylori* infection found in these countries (63, 64). Likewise, the decrease in age-specific CAG prevalence over time suggested by a study from Japan (55) may be related to decreasing *H. pylori* prevalences in younger birth cohorts.

A most crucial aspect in studying the epidemiology of CAG is the type of ascertainment of the diagnosis. In the history of screening for atrophic gastritis, several other methods and markers have also been tested, such as measurement of serum gastrin (65, 66), acid secretion (9), the Azure-A test (67), uropepsin determination (67), and investigation of mucins (2, 3) or multiple serum nutrient levels (68). However, only microscopic histologic assessment and serum pepsinogen measurement (occasionally in combination with *H. pylori* serology) are widely used today.

Considering gastroscopy with subsequent histologic investigation of biopsies, the grading scheme used for defining gastritis has to be taken into account. The Sydney system (69-71) and the Whitehead classification (72, 73) are used most

Table 2. Pepsinogen-based studies

Authors, year (ref.*)	Study population				Prevalence of pepsinogen defined CAG in %			Criteria for diagnosis
	Country (time of survey)	Setting	No. participants (gender), response rate	Age (mean [†])	Overall (severe)	By sex (severe)	By age [‡] (severe)	
Krasinski et al., 1986 (29, 30)	USA (1981-1984)	Elderly people (recruited via advertising)	359 (M, 34.8%; F, 65.2%)	60-99 (76 ± 9)	31.5 (8.1)		60-69: 24.0 (4.8) 70-79: 31.7 (7.3) 80-99: 37.1 (11.1)	all: PGI/PGII <2.9 sev: (PGI/PGII <2.9 and PGI <20 ng/ml)
Burr et al., 1987 (31)	UK	Two towns with different GC-death rate (GP lists)	513 (only men), 75%	65-74 (69)	(7.7) [§] (14.5) [§]			sev: PGI <20 ng/ml
Palli et al., 1991 (32)	Italy (1985-1989)	Population registry based (four regions)	930 (M, 58 %; F, 42 %), 61%	35-74 (58.9)	12.1 (5.8)	M, 13.3 (6.5); F, 10.5 (4.9)	35-49: 5.6 (1.3) 50-64: 9.9 (4.5) 65-74: 18.6 (10.0)	all: (PGI >20 ng/ml and PGI/PGII ≤2.9) or PGI ≤20 ng/ml sev: PGI ≤20 ng/ml
Fukao et al., 1993 (33, 34)	Japan (1991-1992)	Blood donors (four regions)	1,815 (M, 51.2%; F, 48.8%)		13-38	M, 13.9-38.8 5; F, 12.3-37.8 5	Age: male/ female 16-19: 3-13/5-15 20-29: 5-20/0-20 30-39: 10-40/3 -33 40-49: 17-42/12-45 50-59: 22-66/15-62 60-64: 26-62/28-69	all: PGI <70 ng/ml and PGI/PGII <3.0
Tsugane et al., 1993 (35, 36)	Japan (1989-1991)	Population registry based (five regions)	624 (only men), 60-80%	40-49	9.4-26.6			all: PGI <70 ng/ml and PGI/PGII <3.0
Webb et al., 1994 (37-39)	13 nations [¶] (17 populations) (1989-1991)	Population registry offices; GP lists; driver's license rosters; health screenings	3,195 (M/F, ~50%/50%)	25-34 and 55-64	(4.8)	M, (4.1) [¶] ; F, (5.5) [¶]	25-34: (2.1) [¶] 55-64: (7.5) [¶]	sev: PGI <25 ng/ml
	Europe		2,410		(3.3)	M, (2.4) [¶] ; F, (4.2) [¶]	25-34: (1.3) [¶] 55-64: (5.3) [¶]	
	Japan		386		(6.1)	M, (7.5) [¶] ; F, (4.8) [¶]	25-34: (1.5) [¶] 55-64: (10.8) [¶]	
	US		198		(1.5)	M, (1.1) [¶] ; F, (2.0) [¶]	25-34: (0) [¶] 55-64: (3.1) [¶]	
	Algeria		200		(14.2)	M, (10.7) [¶] ; F, (20.0) [¶]	25-34: (10.4) [¶] 55-64: (16.0) [¶]	
Knight et al., 1995 (40, 41)	UK	Industry workers (recruited from four factories)	420 (only men)	18-63 (40)	(3.1)			moderate and severe: PGI/PGII <2.5
Schlemper et al., 1995 (42)	the Netherlands (1991)	Medical examination at workplace	498 (M, 85%; F, 15%), 95%	22-71 (48)	3.6 (1.6)			all: PGI/PGII <1.3 sev: PGI <17 ng/ml
	Japan (1988)		225 (M, 84%; F, 16%), 99%		32.4 (4.4)			
Aromaa et al., 1996 (43)	Finland (1968-1972)	Health screening (controls for cancer cases)	146 (M, 63.7%; F, 36.3%), 82.5%	≥15 (61)	19.9			all: PGI <49 ng/ml
Watanabe et al., 1997 (44)	Japan (1987)	Annual health examination	1,290 (M, 34.3%; F, 65.7%)	≥35	40.4	M, 41; F, 40	Age: male/ female 35-39: 20/14 40-49: 32/29 50-59: 44/39 60-69: 38/42 70-79: 45/52 ≥80: 41/43	all: PGI ≤70 ng/ml and PGI/PGII ≤3.0

(Continued on the following page)

Table 2. Pepsinogen-based studies (Cont'd)

Authors, year (ref.*)	Study population				Prevalence of pepsinogen defined CAG in %			Criteria for diagnosis
	Country (time of survey)	Setting	No. participants (gender), response rate	Age (mean [†])	Overall (severe)	By sex (severe)	By age [‡] (severe)	
Hurwitz et al., 1997 (45)	USA (1991-1993)	"Volunteers" (older adults; recruited via advertising)	243 (M, 29%; F, 71%)	65-96 (79)	9 (5)			all: PGI/PGII <2.9 sev: PGI <20 ng/ml sev: PGI <25 ng/ml
Varis et al., 1998 (46)	Finland (1985-1988)	Smokers (population registry based)	29,133 (only men)	50-69 (57)	(6.0)			
van Asselt et al., 1998 (47)	the Netherlands (1993)	Older adults ("randomly chosen")	105 (M, 44%; F, 56%)	74-80 (76)	32.4 (12.7)			all: PGI/PGII <1.6 sev: PGI/PGII <1.6 and PGI <17 ng/ml
Tsugane et al., 1999 (48)	Japanese in Brazil (1989)	Population registry based	168 (M, 48%; F, 52%), 64%	40-59	39.3 (25.0)	M, 33.3 (22.2); F, 44.8 (27.6)	40-49: 31.9 (26.6) 50-59: 48.7 (23.0)	all: PGI <70 ng/ml and PGI/PGII <3.0 sev: PGI <30 ng/ml
	Japanese in Peru (1995)		110 (M, 38%; F, 62%), 80%			M, 16.7 (16.7); F, 19.1 (4.4)	40-49: 11.4 (9.1) 50-59: 22.7 (9.1)	
Kuwahara et al., 2000 (49)	Japan (1993-1994)	Self-defense forces (pre-retirement examination)	566 (only men)	50-55	35.7 (17.1)			all: PGI <70 ng/ml and PGI/PGII <3.0 sev: PGI <70 ng/ml and PGI/P GII <2.0
Namekata et al., 2000 (50)	Japanese in USA (1994)	CVD-screening	776 (M, 53.5 %; F, 46.5 %)	20-86		M, 14.5; F, 11.9	Age: male/ female <50: 3/2 50-64: 15/16 65-74: 28/20 75-82: 35/37	all: PGI <70 ng/ml and PGI/PGII <3.0
Shibata et al., 2000 (51)	Japan (1997)	Health screening	636 (M, 39%; F, 61%), 71%	30-64	34.1	M, 33.5; F, 34.5	age: male/ female 30-34: 8/11 35-39: 12/23 40-44: 22/25 45-49: 31/27 50-54: 39/32 55-59: 33/39 60-64: 51/49	all: PGI <70 ng/ml and PGI/PGII <3.0
Ito et al., 2000 (52)	Japan (1997)	Health checkup	210 (M, 38%; F, 62%)	40 to ≥70	44	M, 46.3; F, 44.6	Age: male/ female 40-49: 36.8/44.2 50-59: 43.5/55.6 60-69: 50.0/31.4 ≥70: 41.7/42.9	all: PGI ≤70 ng/ml and PGI/PGII ≤3.0
Shibata et al., 2002 (53)	Japan (1993)	Health screening	954 (M, 33%; F, 67%), 47%	30-79	26.6	M, 30.1; F, 24.9	Age: male/ female 30-39: 0/7 40-49: 13/19 50-59: 26/21 60-69: 37/28 70-79: 38/45	all: PGI <70 ng/ml and PGI/PGII <3.0
Sipponen et al., 2003 (54)	Finland (1994-1996)	Population registry based	12,252 (only men)	51-65	(5.2)			sev: PGI <25 ng/ml
Kobayashi et al., 2004 (55)	Japan (1989)	Health checkup	4,486	20-59			Age: male/ female 20-29: 9/11 30-39: 20/23 40-49: 30/51 50-59: 45/38	all: PGI ≤70 ng/ml and PGI/PGII ≤3.0
	Japan (1996)		4,506				Age: male/female 20-29: 3/3	

(Continued on the following page)

Table 2. Pepsinogen-based studies (Cont'd)

Authors, year (ref.*)	Study population				Prevalence of pepsinogen defined CAG in %			Criteria for diagnosis
	Country (time of survey)	Setting	No. participants (gender), response rate	Age (mean [†])	Overall (severe)	By sex (severe)	By age [‡] (severe)	
							30-39: 5/5 40-49: 12/14 50-59: 25/27	
Ohata et al., 2004 (56)	Japan (1994-1995)	Annual health checkup	4,655 (only men)	40-59 (50)	28.9			all: PGI <70 ng/ml and PGI/PGII <3.0
Sato et al., 2004 (57)	Japan (1997)	Annual health checkup	438 (only men)	39-60 (48)	19.6			all: PGI ≤70 ng/ml and PGI/PGII ≤3.0
Kikuchi et al., 2005 (58)	Japan (1988-1990)	Controls for cancer cases (health checkup based)	633 (M, 55%; F, 45%)	40 to ≥70	60 (29)	M, 61 (31); F, 58 (27)	Age: male/female 40-49: 41 (12)/38 (10) 50-59: 61 (27)/57 (27) 60-69: 61 (30)/60 (28) ≥70: 64 (39)/67 (39)	all: (PGI <70 ng/ml and PGI/PGII <3.0) or (PGI <50 ng/ml and PGI/PGII <2.0) sev: PGI < 50 ng/ml and PGI/PGII < 2.0
Green et al., 2005 (59)	New Zealand (1997)	Population registry based	466 (M, 49%; F, 51%), 53%	≥65	6.7 (3.1)			all: PGI/PGII ≤2.9 sev: PGI/PGII ≤2.9 and PGI <20 ng/ml
Aoki et al., 2005 (60)	Japan (1991)	Health checkup	859 (M, 37%; F, 63%)	20-87 (60)			Age: male/female ≤29: 8/18 30-39: 21/41 40-49: 41/43 50-59: 50/47 60-69: 61/55 ≥70: 58/59	all: PGI ≤70 ng/ml and PGI/PGII ≤3.0
	China (1996-1997)	Health survey	1,741 (M, 37%; F, 63%)	17-85 (43)			Age: male/female ≤29: 5/9 30-39: 11/10 40-49: 11/7 50-59: 17/11 60-69: 19/18 ≥70: 29/19	
	Tanzania (2001)	All inhabitants of four villages	573 (M, 43%; F, 57%), 100%	7-90 (24)			Age: male/female ≤29: 29/32 30-39: 21/35 40-49: 24/37 50-59: 11/56 60-69: 39/47 ≥70: 27/41	
	Dominican Republic (2001-2002)	All inhabitants of randomly selected communities	1,215 (M, 37%; F, 63%), 100%	14-92 (33)			Age: male/female ≤29: 13/13 30-39: 14/23 40-49: 33/31 50-59: 24/29 60-69: 25/26 ≥70: 37/21	

Abbreviations: all, mild, moderate, and severe forms of CAG; CVD, cardiovascular disease; F, female; GC, gastric cancer; GP, general practitioner; Hp-gastritis, *H. pylori*-induced gastritis; M, male; sev, severe form of CAG.

*When multiple references are listed: the first publication contains data on prevalence rates, the others contain information on additional extracted study details.

[†]Median (instead of mean) in Knight et al. (40), Varis et al. (46), van Asselt et al. (47) and Aoki et al. (60).

[‡]Age-stratified data were derived from graphs in Fukao et al. (33), Kobayashi et al. (55) and Aoki et al. (60).

§The two different prevalence rates refer to the two examined towns with different stomach cancer death-rates.

||Variations refer to different regions (the overall values are age adjusted for the different regions).

¶Prevalences in the different populations are alphabetically listed in detail in the following [with the following structure: country (city): young males/young females/old males/old females]: Algeria (Algiers): 4.4/20.4/12.5/19.6; Belgium (Ghent): 0/1.9/0/3.9; Denmark (Copenhagen): 0/2.7/2.9/2.9; Germany (Augsburg): 0/0/5.6/8.5; Germany (Deggendorf): 0/1.7/4.4/4.4; Germany (Mosbach): 0/0/2.5/4.6; Greece (Crete): 0/0/8.3/9.8; Iceland (S Region): 2.1/3.9/3.9/5.8; Italy (Florence): 2.2/0/5.6/3.7; Japan (Miyagi): 0/0/17.8/4.8; Japan (Yokote): 2.0/4.0/10.2/10.2; Poland (Adamowka): 0/4.6/5.3/12.5; Portugal (Gaia): 0/3.3/5.4/9.7; Slovenia (Ljubljana): 0/6.1/6.3/10.0; United Kingdom (Oxford): 0/0/2.4/8.3; United Kingdom (Stoke): 2.1/3.9/4.1/5.9; United States (Minneapolis-St. Paul): 0/0/2.1/4.0.

frequently, but a number of authors included in this review also applied other criteria (11, 22, 28, 74-78). Knowledge about the method of extraction of biopsies (blind or under view) and number and location of biopsy sites is of great importance because these aspects have a major influence on results as shown by Kimura et al. (79) and Satoh et al. (80). Unfortunately, the few reported studies showed quite substantial variation in biopsy sites. Optimal biopsy quality and proper orientation are further prerequisites for reliable grading (81), and even the two

sides of a biopsy may lead to different results (intrabiopsy variability; ref. 82).

Although biopsy via gastroscopy is often considered to be the gold standard for diagnosing CAG, definition and usage of the terms "atrophic gastritis" and "gastric atrophy" (83-85) are often inconsistent and intraobserver and interobserver variation concerning presence and severity of atrophy is rather large (86). This is true both for pathologists using individual criteria (87) and for those relying on general

criteria of the (original and updated) Sydney system (81, 88-90), partly caused by their training in different cultures (Asia and Western countries) with different working hypotheses (85). A new classification and scoring system published in 2002 by Rugge et al. (85, 91) and a morphometric assessment of antral atrophy (92) yet have to be validated. Apart from these difficulties, the procedure of biopsy sampling via gastroscopy is rather unpleasant. Although the feasibility of population-based gastroscopy screenings has been proven in areas of high risk for *H. pylori*, CAG, and gastric cancer, such as Iran (28), China (22), and Columbia (19), the realization of such large-scale screenings seems unlikely in Western countries with a low risk for CAG and gastric cancer.

In contrast, screenings based on pepsinogen measurements, which are both less expensive and less invasive, have been conducted successfully in several European countries (31, 32, 40, 43, 46, 47, 54). In Japan, about five million people are screened annually for gastric cancer by X-rays (93). In this high-risk country, measurement of serum pepsinogen concentrations may provide an opportunity to include larger proportions of the population in stomach cancer examination programs (94).

The use of a number of different definitions and cutoff values limits comparability of studies relying on pepsinogen concentrations. Early studies establishing cutoff values were conducted by Samloff et al. (9) in 1982 and Miki et al. in 1987 (95) and 1989 (96). In most studies included in this review, CAG was defined by a combination of the PG I concentration and the ratio of PG I to PG II. However, some studies relied solely on the PG I concentration (measuring exclusively corpus atrophy), and some others relied solely on the PG I/PG II ratio. Furthermore, the cutoff values widely differed among the studies: 70 ng/mL (indicating mild, moderate, and severe CAG) was most frequently used as PG I threshold, but there are also studies using 17, 20, or 25 ng/mL (indicating exclusively severe CAG) and one study each with 30, 49, and 50 ng/mL, a pattern that inevitably leads to differences in prevalence estimates. In contrast, the threshold for the PG I/PG II ratio was 3.0 (or 2.9) mostly, but a threshold of 1.3, 1.6, 2.0, and 2.5 was also used in single studies (40, 42, 47, 49, 58).

Specificity and sensitivity of the CAG diagnosis via serum pepsinogen concentrations have been investigated in numerous studies. Samloff et al. (9) predicted the correct mucosal status in 70% of biopsies according to his established cutoff values. Dinis-Ribeiro et al. (10) published a meta-analysis on the validity of pepsinogen tests in 2004 and found that a combination of both PG I and PG I/PG II ratio was required to achieve homogenous high levels of sensitivity and specificity. It is important to bear in mind that all validations refer to comparison with gastroscopy and histologic assessment, which itself cannot claim to be free of inaccuracy. A possible drawback of pepsinogen levels is their possible dependence of additional factors that are difficult to identify. Several studies have shown that smoking elevates both the PG I level and the PG I/PG II ratio (97), and this effect seems to depend on the status of *H. pylori* infection (98). The influence of alcohol is not yet clear (97). Interestingly, pepsinogen concentrations measured in some parts of Asia partly seem to be higher in general than those in Western countries: in Linqiu (China) where CAG is virtually universal, median PG I levels exceeded 90 ng/mL (probably not due to assay procedures; ref. 23), whereas they are usually below 70 ng/mL in European countries (99). Furthermore, the only pepsinogen-based study from China included in this review would suggest much lower CAG prevalences than the multiple gastroscopy-based studies from this country. Different patterns of location and spread of CAG have been forwarded as possible explanations and may compromise the

use of pepsinogen levels for international comparative studies.

In this review, only studies published as full articles were included. Most likely, additional results have been presented at conferences and published as meeting proceedings, but the lack of detail and accessibility of pertinent publications would not have allowed comparably detailed presentation of methods and results of those studies in this review.

In conclusion, despite the limited number and comparability of studies, this review indicates that CAG is relatively common among older adults in different parts of the world, but large variations exist. Particularly high prevalences even among younger adults are found in some high-risk regions of gastric cancer in Asia. Large-scale international comparative studies with standardized methodology to determine CAG are needed to provide a more coherent and complete picture of the epidemiology of CAG. Noninvasive measurements of CAG by combined measurement of PG I and the PG I/PG II ratio and potentially additional serum markers may be particularly suited for population-based studies but may require careful consideration of potentially different patterns of CAG in different parts of the world.

Appendix 1

Studies excluded from this review because of:

(A) Preselection of the study population

1. Risk factors for atrophic chronic gastritis in a European population: results of the Eurohepygast study. *Gut* 2002;50:779-85.
2. Asaka M, Sugiyama T, Nobuta A, Kato M, Takeda H, and Graham DY. Atrophic gastritis and intestinal metaplasia in Japan: results of a large multicenter study. *Helicobacter* 2001;6:294-9.
3. Beales IL, Crabtree JE, Scunes D, Covacci A, and Calam J. Antibodies to CagA protein are associated with gastric atrophy in *Helicobacter pylori* infection. *Eur J Gastroenterol Hepatol* 1996;8:645-9.
4. Chang-Claude J, Raedsch R, Waldherr R, et al. Prevalence of *Helicobacter pylori* infection and gastritis among young adults in China. *Eur J Cancer Prev* 1995;4:73-9.
5. Chen XY, van Der Hulst RW, Shi Y, Xiao SD, Tytgat GN, and Ten Kate FJ. Comparison of precancerous conditions: atrophy and intestinal metaplasia in *Helicobacter pylori* gastritis among Chinese and Dutch patients. *J Clin Pathol* 2001;54:367-70.
6. Dursun M, Yilmaz S, Yukselen V, Kilinc N, Canoruc F, and Tuzcu A. Evaluation of optimal gastric mucosal biopsy site and number for identification of *Helicobacter pylori*, gastric atrophy and intestinal metaplasia. *Hepatogastroenterology* 2004;51:1732-5.
7. Fontham ET, Ruiz B, Perez A, Hunter F, and Correa P. Determinants of *Helicobacter pylori* infection and chronic gastritis. *Am J Gastroenterol* 1995;90:1094-101.
8. Fung WP, Lee SK, and Tye CY. The prevalence of chronic gastritis in patients with gastric ulcer. *Aust N Z J Med* 1975;5:133-7.
9. Haruma K, Kamada T, Kawaguchi H, et al. Effect of age and *Helicobacter pylori* infection on gastric acid secretion. *J Gastroenterol Hepatol* 2000;15:277-83.
10. Hu PJ, Li YY, Lin HL, et al. Gastric atrophy and regional variation in upper gastrointestinal disease. *Am J Gastroenterol* 1995;90:1102-6.
11. Jaskiewicz K, Louwrens HD. Chronic atrophic gastritis in a population at risk for gastric carcinoma. *Anticancer Res* 1991;11:835-9.

12. Kato I, Tominaga S, Ito Y, et al. Atrophic gastritis and stomach cancer risk: cross-sectional analyses. *Jpn J Cancer Res* 1992;83:1041-6.
 13. Kaur G, Raj SM. A study of the concordance between endoscopic gastritis and histological gastritis in an area with a low background prevalence of *Helicobacter pylori* infection. *Singapore Med J* 2002;43:090-2.
 14. Kawaguchi H, Haruma K, Komoto K, Yoshihara M, Sumii K, Kajiyama G. *Helicobacter pylori* infection is the major risk factor for atrophic gastritis. *Am J Gastroenterol* 1996;91:959-62.
 15. Kiyohira K, Yoshihara M, Ito M, Haruma K, Tanaka S, Chayama K. Serum pepsinogen concentration as a marker of *Helicobacter pylori* infection and the histologic grade of gastritis; evaluation of gastric mucosa by serum pepsinogen levels. *J Gastroenterol* 2003;38:332-8.
 16. Kohlstadt IC, Antunez de Mayolo EA, Ramirez-Icaza C. Parietal cell antibodies among Peruvians with gastric pathologic changes. *Gastrointestinal Physiology Working Group. Scand J Gastroenterol* 1993;28:973-7.
 17. Lee CH, Bang SH, Lee SK, Song KY, Lee IC. Gene expression profiling reveals sequential changes in gastric tubular adenoma and carcinoma *in situ*. *World J Gastroenterol* 2005;11:1937-45.
 18. Matsukura N, Onda M, Tokunaga A, et al. Significance of serum markers pepsinogen I and II for chronic atrophic gastritis, peptic ulcer, and gastric cancer. *J Clin Gastroenterol* 1993;17 Suppl 1:S146-50.
 19. Mihara M, Haruma K, Kamada T, et al. The role of endoscopic findings for the diagnosis of *Helicobacter pylori* infection: evaluation in a country with high prevalence of atrophic gastritis. *Helicobacter* 1999;4:40-8.
 20. Montani A, Sasazuki S, Inoue M, Higuchi K, Arakawa T, and Tsugane S. Food/nutrient intake and risk of atrophic gastritis among the *Helicobacter pylori*-infected population of northeastern Japan. *Cancer Sci* 2003;94:372-7.
 21. Motteram R. A biopsy study of chronic gastritis and gastric atrophy. *J Pathol Bacteriol* 1951;63:389-94.
 22. Munoz N, Vivas J, Buiatti E, Kato I, Oliver W. Chemoprevention trial on precancerous lesions of the stomach in Venezuela: summary of study design and baseline data. *IARC Sci Publ* 1996;125-33.
 23. Ohkuma K, Okada M, Murayama H, et al. Association of *Helicobacter pylori* infection with atrophic gastritis and intestinal metaplasia. *J Gastroenterol Hepatol* 2000;15:1105-12.
 24. Oksanen A, Sipponen P, Miettinen A, Sarna S, Rautelin H. Evaluation of blood tests to predict normal gastric mucosa. *Scand J Gastroenterol* 2000;35:791-5.
 25. Potet F, Florent C, Benhamou E, et al. Chronic gastritis: prevalence in the French population. *CIRIG. Gastroenterol Clin Biol* 1993;17:103-8.
 26. Primignani M, Agape D, Ronchi G, et al. Gastric histology and function tests in Italian patients with dermatitis herpetiformis. *Scand J Gastroenterol* 1990;25:357-62.
 27. Ricci C, Vakil N, Rugge M, et al. Serological markers for gastric atrophy in asymptomatic patients infected with *Helicobacter pylori*. *Am J Gastroenterol* 2004;99:1910-5.
 28. Ricuarte O, Gutierrez O, Cardona H, Kim JG, Graham DY, El-Zimaity HM. Atrophic gastritis in young children and adolescents. *J Clin Pathol* 2005;58:1189-93.
 29. Rugge M, Busatto G, Cassaro M, et al. Patients younger than 40 years with gastric carcinoma: *Helicobacter pylori* genotype and associated gastritis phenotype. *Cancer* 1999;85:2506-11.
 30. Rugge M, Cassaro M, Leandro G, et al. *Helicobacter pylori* in promotion of gastric carcinogenesis. *Dig Dis Sci* 1996;41:950-5.
 31. Ruiz B, Correa P, Fontham ET, Ramakrishnan T. Antral atrophy, *Helicobacter pylori* colonization, and gastric pH. *Am J Clin Pathol* 1996;105:96-101.
 32. Satoh K, Kimura K, Sipponen P. *Helicobacter pylori* infection and chronological extension of atrophic gastritis. *Eur J Gastroenterol Hepatol* 1995;7 Suppl 1:S11-5.
 33. Shimoyama T, Fukuda S, Tanaka M, Mikami T, Saito Y, Munakata A. High prevalence of the CagA-positive *Helicobacter pylori* strains in Japanese asymptomatic patients and gastric cancer patients. *Scand J Gastroenterol* 1997;32:465-8.
 34. Sipponen P, Helske T, Jarvinen P, Hyvarinen H, Seppala K, Siurala M. Fall in the prevalence of chronic gastritis over 15 years: analysis of outpatient series in Finland from 1977, 1985, and 1992. *Gut* 1994;35:1167-71.
 35. Sipponen P, Samloff IM, Saukkonen M, Varis K. Serum pepsinogens I and II and gastric mucosal histology after partial gastrectomy. *Gut* 1985;26:1179-82.
 36. Sitas F, Smallwood R, Jewell D, et al. Serum anti-*Helicobacter pylori* IgG antibodies and pepsinogens A and C as serological markers of chronic atrophic gastritis. *Cancer Epidemiol Biomarkers Prev* 1993;2:119-23.
 37. Sobala GM, Pignatelli B, Schorah CJ, et al. Levels of nitrite, nitrate, N-nitroso compounds, ascorbic acid and total bile acids in gastric juice of patients with and without precancerous conditions of the stomach. *Carcinogenesis* 1991;12:193-8.
 38. Stahel E, Gyr K, Jallah E, Heitz P. Gastroduodenitis and peptic ulcer in a rural Liberian community. An endoscopic prospective study. *Trop Geogr Med* 1981;33:155-60.
 39. Suriani R, Venturini I, Taraglio S, et al. Type III intestinal metaplasia, *Helicobacter pylori* infection and gastric carcinoma risk index in an Italian series of 1750 patients. *Hepatogastroenterology* 2005;52:285-8.
 40. Tamm A, Villako K, Harkonen M, Karonen SL. Serum pepsinogen I and the state of gastric mucosa in an Estonian population sample. *Scand J Gastroenterol* 1984;19:1091-4.
 41. Tatsuta M, Iishi H, Nakaizumi A, et al. Fundal atrophic gastritis as a risk factor for gastric cancer. *Int J Cancer* 1993;53:70-4.
 42. Topal D, Goral V, Yilmaz F, Kara IH. The relation of *Helicobacter pylori* with intestinal metaplasia, gastric atrophy and BCL-2. *Turk J Gastroenterol* 2004;15:149-55.
 43. Varis O, Valle J, Siurala M. Is *Helicobacter pylori* involved in the pathogenesis of the gastritis characteristic of pernicious anaemia? Comparison between pernicious anaemia relatives and duodenal ulcer relatives. *Scand J Gastroenterol* 1993;28:705-8.
 44. Zaitoun AM. Histological study of chronic gastritis from the United Arab Emirates using the Sydney system of classification. *J Clin Pathol* 1994;47:810-5.
- (B) Size of the study population
1. Andrews GR, Haneman B, Arnold BJ, Booth JC, Taylor K. Atrophic gastritis in the aged. *Australas Ann Med* 1967;16:230-5.
 2. Earlam RJ, Amerigo J, Kakavoulis T, Pollock DJ. Histological appearances of oesophagus, antrum and duodenum and their correlation with symptoms in patients with a duodenal ulcer. *Gut* 1985;26:95-100.
 3. Palmer ED. The state of the gastric mucosa of elderly persons without upper gastrointestinal symptoms. *J Am Geriatr Soc* 1954;2:171-3.

4. Russell PK, Aziz MA, Ahmad N, Kent TH, Gangarosa EJ. Enteritis and gastritis in young asymptomatic Pakistani men. *Am J Dig Dis* 1966;11:296-306.

References

1. Ferlay JB, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide. IARC CancerBase No. 5, version 2.0 (<http://www-dep.iarc.fr/>). Lyon: IARC Press; 2004.
2. Correa P. A human model of gastric carcinogenesis. *Cancer Res* 1988;48:3554-60.
3. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process—First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. *Cancer Res* 1992;52:6735-40.
4. Satoh K, Kimura K, Sipponen P. *Helicobacter pylori* infection and chronological extension of atrophic gastritis. *Eur J Gastroenterol Hepatol* 1995;7 Suppl 1:S11-5.
5. Rugge M, Cassaro M, Leandro G, et al. *Helicobacter pylori* in promotion of gastric carcinogenesis. *Dig Dis Sci* 1996;41:950-5.
6. Parsonnet J, Samloff IM, Nelson LM, Orentreich N, Vogelstein JH, Friedman GD. *Helicobacter pylori*, pepsinogen, and risk for gastric adenocarcinoma. *Cancer Epidemiol Biomarkers Prev* 1993;2:461-6.
7. Brenner H, Arndt V, Stegmaier C, Ziegler H, Rothenbacher D. Is *Helicobacter pylori* infection a necessary condition for noncardia gastric cancer? *Am J Epidemiol* 2004;159:252-8.
8. Sipponen P. Update on the pathologic approach to the diagnosis of gastritis, gastric atrophy, and *Helicobacter pylori* and its sequelae. *J Clin Gastroenterol* 2001;32:196-202.
9. Samloff IM, Varis K, Ihamaki T, Siurala M, Rotter JI. Relationships among serum pepsinogen I, serum pepsinogen II, gastric mucosal histology. A study in relatives of patients with pernicious anemia. *Gastroenterology* 1982;83:204-9.
10. Dinis-Ribeiro M, Yamaki G, Miki K, Costa-Pereira A, Matsukawa M, Kurihara M. Meta-analysis on the validity of pepsinogen test for gastric carcinoma, dysplasia or chronic atrophic gastritis screening. *J Med Screen* 2004;11:141-7.
11. Siurala M, Isokoski M, Varis K, Kekki M. Prevalence of gastritis in a rural population. Bioptic study of subjects selected at random. *Scand J Gastroenterol* 1968;3:211-23.
12. Villako K, Tamm A, Savisaar E, Ruttas M. Prevalence of antral and fundic gastritis in a randomly selected group of an Estonian rural population. *Scand J Gastroenterol* 1976;11:817-22.
13. Kreuning J, Bosman FT, Kuiper G, Wal AM, Lindeman J. Gastric and duodenal mucosa in 'healthy' individuals. An endoscopic and histopathological study of 50 volunteers. *J Clin Pathol* 1978;31:69-77.
14. Ihamaki T, Varis K, Siurala M. Morphological, functional and immunological state of the gastric mucosa in gastric carcinoma families. Comparison with a computer-matched family sample. *Scand J Gastroenterol* 1979;14:801-12.
15. Cheli R, Simon L, Aste H, et al. Atrophic gastritis and intestinal metaplasia in asymptomatic Hungarian and Italian populations. *Endoscopy* 1980;12:105-8.
16. Villako K, Kekki M, Tamm A, et al. Epidemiology and dynamics of gastritis in a representative sample of an Estonian urban population. *Scand J Gastroenterol* 1982;17:601-7.
17. Villako K, Maards H, Tammur R, et al. *Helicobacter (Campylobacter) pylori* infestation and the development and progression of chronic gastritis: results of long-term follow-up examinations of a random sample. *Endoscopy* 1990;22:114-7.
18. Cheli R, Giacosa A. Duodenal ulcer and chronic gastritis. *Endoscopy* 1986;18:125-6.
19. Correa P, Haenszel W, Cuello C, et al. Gastric precancerous process in a high risk population: cross-sectional studies. *Cancer Res* 1990;50:4731-6.
20. Johnsen R, Bernersen B, Straume B, Forde OH, Bostad L, Burhol PG. Prevalences of endoscopic and histological findings in subjects with and without dyspepsia. *BMJ* 1991;302:749-52.
21. Bernersen B, Johnsen R, Straume B, Burhol PG, Jenssen TG, Stakkevold PA. Towards a true prevalence of peptic ulcer: the Sorreisa gastrointestinal disorder study. *Gut* 1990;31:989-92.
22. You WC, Blot WJ, Li JY, et al. Precancerous gastric lesions in a population at high risk of stomach cancer. *Cancer Res* 1993;53:1317-21.
23. You WC, Blot WJ, Zhang L, et al. Serum pepsinogens in relation to precancerous gastric lesions in a population at high risk for gastric cancer. *Cancer Epidemiol Biomarkers Prev* 1993;2:113-7.
24. Kataleris PH, Seow F, Lin BP, Napoli J, Ngu MC, Jones DB. Effect of age, *Helicobacter pylori* infection, and gastritis with atrophy on serum gastrin and gastric acid secretion in healthy men. *Gut* 1993;34:1032-7.
25. Asaka M, Kato M, Kudo M, et al. Atrophic changes of gastric mucosa are caused by *Helicobacter pylori* infection rather than aging: studies in asymptomatic Japanese adults. *Helicobacter* 1996;1:52-6.
26. You WC, Zhang L, Gail MH, et al. Precancerous lesions in two counties of China with contrasting gastric cancer risk. *Int J Epidemiol* 1998;27:945-8.
27. Borch K, Jonsson KA, Petersson F, Redeen S, Mardh S, Franzen LE. Prevalence of gastroduodenitis and *Helicobacter pylori* infection in a general population sample: relations to symptomatology and life-style. *Dig Dis Sci* 2000;45:1322-9.
28. Malekzadeh R, Sotoudeh M, Derakhshan MH, et al. Prevalence of gastric precancerous lesions in Ardabil, a high incidence province for gastric adenocarcinoma in the northwest of Iran. *J Clin Pathol* 2004;57:37-42.
29. Krasinski SD, Russell RM, Samloff IM, et al. Fundic atrophic gastritis in an elderly population. Effect on hemoglobin and several serum nutritional indicators. *J Am Geriatr Soc* 1986;34:800-6.
30. Jacques PF, Hartz SC, McGandy RB, Jacob RA, Russell RM. Vitamin C and blood lipoproteins in an elderly population. *Ann N Y Acad Sci* 1987;498:100-9.
31. Burr ML, Samloff IM, Bates CJ, Holliday RM. Atrophic gastritis and vitamin C status in two towns with different stomach cancer death-rates. *Br J Cancer* 1987;56:163-7.
32. Palli D, Decarli A, Cipriani F, et al. Plasma pepsinogens, nutrients, and diet in areas of Italy at varying gastric cancer risk. *Cancer Epidemiol Biomarkers Prev* 1991;1:45-50.
33. Fukao A, Hisamichi S, Ohsato N, Fujino N, Endo N, Iha M. Correlation between the prevalence of gastritis and gastric cancer in Japan. *Cancer Causes Control* 1993;4:17-20.
34. Fukao A, Komatsu S, Tsubono Y, et al. *Helicobacter pylori* infection and chronic atrophic gastritis among Japanese blood donors: a cross-sectional study. *Cancer Causes Control* 1993;4:307-12.
35. Tsugane S, Kabuto M, Imai H, et al. *Helicobacter pylori*, dietary factors, and atrophic gastritis in five Japanese populations with different gastric cancer mortality. *Cancer Causes Control* 1993;4:297-305.
36. Tsugane S, Gey F, Ichinowatari Y, et al. Cross-sectional epidemiologic study for assessing cancer risks at the population level. I. Study design and participation rate. *J Epidemiol* 1992;2:75-81.
37. Webb PM, Hengels KJ, Moller H, et al. The epidemiology of low serum pepsinogen A levels and an international association with gastric cancer rates. EUROGAST Study Group. *Gastroenterology* 1994;107:1335-44.
38. Epidemiology of, and risk factors for, *Helicobacter pylori* infection among 3194 asymptomatic subjects in 17 populations. The EUROGAST Study Group. *Gut* 1993;34:1672-6.
39. Webb PM, Bates CJ, Palli D, Forman D. Gastric cancer, gastritis and plasma vitamin C: results from an international correlation and cross-sectional study. The Eurogast Study Group. *Int J Cancer* 1997;73:684-9.
40. Knight T, Greaves S, Wilson A, et al. Variability in serum pepsinogen levels in an asymptomatic population. *Eur J Gastroenterol Hepatol* 1995;7:647-54.
41. Knight T, Wyatt J, Wilson A, et al. *Helicobacter pylori* gastritis and serum pepsinogen levels in a healthy population: development of a biomarker strategy for gastric atrophy in high risk groups. *Br J Cancer* 1996;73:819-24.
42. Schlemper RJ, van der Werf SD, Vandenbroucke JP, Biemond I, Lamers CB. Seroprevalence of gastritis in Japanese and Dutch working populations: evidence for the development of atrophic gastritis that is not related to *Helicobacter pylori*. *Gut* 1995;37:199-204.
43. Aromaa A, Kosunen TU, Knekt P, et al. Circulating anti-*Helicobacter pylori* immunoglobulin A antibodies and low serum pepsinogen I level are associated with increased risk of gastric cancer. *Am J Epidemiol* 1996;144:142-9.
44. Watanabe Y, Ozasa K, Higashi A, et al. *Helicobacter pylori* infection and atrophic gastritis. A case-control study in a rural town of Japan. *J Clin Gastroenterol* 1997;25:391-4.
45. Hurwitz A, Brady DA, Schaal SE, Samloff IM, Dedon J, Ruhl CE. Gastric acidity in older adults. *JAMA* 1997;278:659-62.
46. Varis K, Taylor PR, Sipponen P, et al. Gastric cancer and premalignant lesions in atrophic gastritis: a controlled trial on the effect of supplementation with alpha-tocopherol and beta-carotene. The Helsinki Gastritis Study Group. *Scand J Gastroenterol* 1998;33:294-300.
47. van Asselt DZ, de Groot LC, van Staveren WA, et al. Role of cobalamin intake and atrophic gastritis in mild cobalamin deficiency in older Dutch subjects. *Am J Clin Nutr* 1998;68:328-34.
48. Tsugane S, Fahey MT, Hamada GS, Kabuto M, Miyakawa VY. *Helicobacter pylori* infection and atrophic gastritis in middle-aged Japanese residents of Sao Paulo and Lima. *Int J Epidemiol* 1999;28:577-82.
49. Kuwahara Y, Kono S, Eguchi H, Hamada H, Shinchi K, Imanishi K. Relationship between serologically diagnosed chronic atrophic gastritis, *Helicobacter pylori*, and environmental factors in Japanese men. *Scand J Gastroenterol* 2000;35:476-81.
50. Namekata T, Miki K, Kimmey M, et al. Chronic atrophic gastritis and *Helicobacter pylori* infection among Japanese Americans in Seattle. *Am J Epidemiol* 2000;151:820-30.
51. Shibata K, Moriyama M, Fukushima T, Kaetsu A, Miyazaki M, Une H. Green tea consumption and chronic atrophic gastritis: a cross-sectional study in a green tea production village. *J Epidemiol* 2000;10:310-6.
52. Ito Y, Suzuki K, Ichino N, et al. The risk of *Helicobacter Pylori* infection and atrophic gastritis from food and drink intake: a cross-sectional study in Hokkaido, Japan. *Asian Pac J Cancer Prev* 2000;1:147-56.
53. Shibata K, Moriyama M, Fukushima T, Une H, Miyazaki M, Yamaguchi N. Relation of *Helicobacter pylori* infection and lifestyle to the risk of chronic atrophic gastritis: a cross-sectional study in Japan. *J Epidemiol* 2002;12:105-11.
54. Sipponen P, Laxen F, Huotari K, Harkonen M. Prevalence of low vitamin B12 and high homocysteine in serum in an elderly male population: association with atrophic gastritis and *Helicobacter pylori* infection. *Scand J Gastroenterol* 2003;38:1209-16.

55. Kobayashi T, Kikuchi S, Lin Y, et al. Trends in the incidence of gastric cancer in Japan and their associations with *Helicobacter pylori* infection and gastric mucosal atrophy. *Gastric Cancer* 2004;7:233–9.
56. Ohata H, Kitauchi S, Yoshimura N, et al. Progression of chronic atrophic gastritis associated with *Helicobacter pylori* infection increases risk of gastric cancer. *Int J Cancer* 2004;109:138–43.
57. Sato K, Kawakami N, Ohtsu T, et al. Broccoli consumption and chronic atrophic gastritis among Japanese males: an epidemiological investigation. *Acta Med Okayama* 2004;58:127–33.
58. Kikuchi S, Yagyu K, Obata Y, et al. Serum pepsinogen values and *Helicobacter pylori* status among control subjects of a nested case-control study in the JACC study. *J Epidemiol* 2005;15 Suppl 2:S126–33.
59. Green TJ, Venn BJ, Skeaff CM, Williams SM. Serum vitamin B12 concentrations and atrophic gastritis in older New Zealanders. *Eur J Clin Nutr* 2005;59:205–10.
60. Aoki K, Kihai PE, Wenyuan Z, et al. Comparison of prevalence of chronic atrophic gastritis in Japan, China, Tanzania, and the Dominican Republic. *Ann Epidemiol* 2005;15:598–606.
61. Sipponen P, Kekki M, Haapakoski J, Ihamak T, Siurala M. Gastric cancer risk in chronic atrophic gastritis: statistical calculations of cross-sectional data. *Int J Cancer* 1985;35:173–7.
62. Sipponen P. *Helicobacter pylori* gastritis: epidemiology. *J Gastroenterol* 1997;32:273–7.
63. Zhang L, Blot WJ, You WC, et al. *Helicobacter pylori* antibodies in relation to precancerous gastric lesions in a high-risk Chinese population. *Cancer Epidemiol Biomarkers Prev* 1996;5:627–30.
64. Parkin DM. International variation. *Oncogene* 2004;23:6329–40.
65. Vaananen H, Vauhkonen M, Helske T, et al. Non-endoscopic diagnosis of atrophic gastritis with a blood test. Correlation between gastric histology and serum levels of gastrin-17 and pepsinogen I: a multicentre study. *Eur J Gastroenterol Hepatol* 2003;15:885–91.
66. Varis K, Samloff IM, Ihamak T, Siurala M. An appraisal of tests for severe atrophic gastritis in relatives of patients with pernicious anemia. *Dig Dis Sci* 1979;24:187–91.
67. Isokoski M. Screening for atrophic gastritis. Comparison of the results of azure-A test and uropepsin determination with gastric biopsy in a rural population. *Scand J Gastroenterol* 1969;4:425–33.
68. Haenszel W, Correa P, Lopez A, et al. Serum micronutrient levels in relation to gastric pathology. *Int J Cancer* 1985;36:43–8.
69. Price AB. The Sydney System: histological division. *J Gastroenterol Hepatol* 1991;6:209–22.
70. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. *Am J Surg Pathol* 1996;20:1161–81.
71. Misiewicz JJ. The Sydney System: a new classification of gastritis. Introduction. *J Gastroenterol Hepatol* 1991;6:207–8.
72. Whitehead R, Truelove SC, Gear MW. The histological diagnosis of chronic gastritis in fiberoptic gastroscopy biopsy specimens. *J Clin Pathol* 1972;25:1–11.
73. Whitehead R. *Mucosal biopsy of the gastrointestinal tract*. London: Saunders; 1973.
74. Valencia-Parparcen J, d' Escrivan G, De González M. La gastritis como precursora del cáncer gástrico y otras enfermedades del estómago. *G.E.N.* 1970;3:253–69.
75. Correa P. Chronic gastritis: a clinico-pathological classification. *Am J Gastroenterol* 1988;83:504–9.
76. Correa P, Cuello C, Duque E, et al. Gastric cancer in Colombia. III. Natural history of precursor lesions. *J Natl Cancer Inst* 1976;57:1027–35.
77. Cheli R, Doderio M, Celle G. [Biopic findings and secretory behavior of the gastric mucosa in duodenal ulcer: comparison between fundal glandular morphology and the secretory behavior]. *Minerva Gastroenterol* 1959;5:60–7.
78. Owen DA. The diagnosis and significance of gastritis. *Pathol Annu* 1979;141 Pt:247–71.
79. Kimura K. Chronological transition of the fundic-pyloric border determined by stepwise biopsy of the lesser and greater curvatures of the stomach. *Gastroenterology* 1972;63:584–92.
80. Satoh K, Kimura K, Taniguchi Y, et al. Biopsy sites suitable for the diagnosis of *Helicobacter pylori* infection and the assessment of the extent of atrophic gastritis. *Am J Gastroenterol* 1998;93:569–73.
81. Offerhaus GJ, Price AB, Haot J, et al. Observer agreement on the grading of gastric atrophy. *Histopathology* 1999;34:320–5.
82. Cassaro M, Di Mario F, Leandro G, Genta RM, Rugge M. The dark side of the gastric biopsy. *Hum Pathol* 1999;30:741–4.
83. Genta RM. Recognizing atrophy: another step toward a classification of gastritis. *Am J Surg Pathol* 1996;20 Suppl 1:S23–30.
84. Genta RM. Review article: gastric atrophy and atrophic gastritis—nebulous concepts in search of a definition. *Aliment Pharmacol Ther* 1998;12 Suppl 1: 17–23.
85. Rugge M, Correa P, Dixon MF, et al. Gastric mucosal atrophy: interobserver consistency using new criteria for classification and grading. *Aliment Pharmacol Ther* 2002;16:1249–59.
86. Plummer M, Buiatti E, Lopez G, et al. Histological diagnosis of precancerous lesions of the stomach: a reliability study. *Int J Epidemiol* 1997;26: 716–20.
87. el-Zimaity HM, Graham DY, al-Assi MT, et al. Interobserver variation in the histopathological assessment of *Helicobacter pylori* gastritis. *Hum Pathol* 1999;27:35–41.
88. Andrew A, Wyatt JI, Dixon MF. Observer variation in the assessment of chronic gastritis according to the Sydney system. *Histopathology* 1994;25: 317–22.
89. Chen XY, van der Hulst RW, Bruno MJ, et al. Interobserver variation in the histopathological scoring of *Helicobacter pylori* related gastritis. *J Clin Pathol* 1999;52:612–5.
90. Guarner J, Herrera-Goepfert R, Mohar A, et al. Interobserver variability in application of the revised Sydney classification for gastritis. *Hum Pathol* 1999;30:1431–4.
91. Rugge M, Genta RM. Staging and grading of chronic gastritis. *Hum Pathol* 2005;36:228–33.
92. Ruiz B, Garay J, Johnson W, et al. Morphometric assessment of gastric antral atrophy: comparison with visual evaluation. *Histopathology* 2001;39: 235–42.
93. Miki K, Morita M, Sasajima M, Hoshina R, Kanda E, Urita Y. Usefulness of gastric cancer screening using the serum pepsinogen test method. *Am J Gastroenterol* 2003;98:735–9.
94. Kurosawa M, Kikuchi S, Arisue T, Fukao A. [Effectiveness and feasibility of a strategy for increasing participation in the Japanese Stomach Cancer Examination programs by incorporating serum pepsinogen tests]. *Nippon Koshu Eisei Zasshi* 1998;45:352–60.
95. Miki K, Ichinose M, Shimizu A, et al. Serum pepsinogens as a screening test of extensive chronic gastritis. *Gastroenterol Jpn* 1987;22:133–41.
96. Miki K, Ichinose M, Kawamura N, et al. The significance of low serum pepsinogen levels to detect stomach cancer associated with extensive chronic gastritis in Japanese subjects. *Jpn J Cancer Res* 1989;80: 111–4.
97. Kikuchi S, Inaba Y, Wada O, et al. The association of smoking and drinking habits with serum pepsinogens. *Int J Epidemiol* 1995;24:346–53.
98. Tatemichi M, Kabuto M, Tsugane S. Effect of smoking on serum pepsinogen I level depends on serological status of *Helicobacter pylori*. *Jpn J Cancer Res* 2001;92:243–8.
99. Veenendaal RA, Biemond I, Pena AS, van Duijn W, Kreuning J, Lamers CB. Influence of age and *Helicobacter pylori* infection on serum pepsinogens in healthy blood transfusion donors. *Gut* 1992;33:452–5.

Cancer Epidemiology, Biomarkers & Prevention

AACR American Association
for Cancer Research

Prevalence of Chronic Atrophic Gastritis in Different Parts of the World

Melanie Nicole Weck and Hermann Brenner

Cancer Epidemiol Biomarkers Prev 2006;15:1083-1094.

Updated version Access the most recent version of this article at:
<http://cebp.aacrjournals.org/content/15/6/1083>

Cited articles This article cites 97 articles, 19 of which you can access for free at:
<http://cebp.aacrjournals.org/content/15/6/1083.full#ref-list-1>

Citing articles This article has been cited by 11 HighWire-hosted articles. Access the articles at:
<http://cebp.aacrjournals.org/content/15/6/1083.full#related-urls>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://cebp.aacrjournals.org/content/15/6/1083>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.